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Nowadays, new imaging modalities such as molecular imaging have enabled both 
practitioners and researchers to visualize, trace and measure biological processes at the level of 
cells or even single molecules. Instruments of nuclear medicine, like Positron Emission 
Tomography (PET), Single-Photon Emission Computed Tomography (SPECT) and gamma 
scintigraphy have largely contributed to the evolving and promising era of personalized 
medicine. Such recently introduced molecular imaging techniques take advantage of an 
additional potential for broad application in imaging molecular or cellular events in vivo: 
gene/protein function and regulation, signal transduction, transcriptional regulation and 
characterization of transgenic animals (Jacobs et al., 2003). Most importantly, molecular 
imaging will render possible the identification of potential molecular therapeutic targets, in the 
development of new treatment strategies, and in their successful implementation into clinical 
application (Jacobs et al., 2003). As a description, molecular imaging is a process of getting 
signals originating from live organisms after the administration of specific agents that target 
specific markers found at tissue or cellular level. Such nuclear imaging is the most well-known 
instrument of all molecular imaging methods and has been set as the gold standard. 
In this chapter, the authors will discuss PET and other more recent molecular imaging 
techniques such as near infrared fluorescence (NIRF). Moreover, we will put emphasis on 
the application of molecular imaging in visualization of stem cell transplantation as a 
ground breaking treatment modality for neurodegenerative and other neurological diseases.  
The authors stand among the very first who has implemented recently introduced 
molecular imaging techniques into experimental research and clinical practice.  
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2. Cell therapy 
Cell therapy, as a promising method using live components of human tissue for treatment of 
neurological diseases, is one of the mainstays of the wide field of regenerative medicine.. 
Among stem cell sources available up to date, mesenchymal stem cells (MSCs) have 
generated a great deal of interest because of their potency in terms of regeneration and 
tissue engineering (Wislet-Gendebien et al., 2012). 
Neurodegenerative disease is a term which encompasses a wide range of acute and chronic 
neurological diseases such as Parkinson's disease, Huntington's disease, amyotrophic lateral 
sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), stroke, and spinal cord injury. 
Because of the fact that central nervous system reveals limited capacity of regeneration and 
tissue replacement, cell therapy and tissue regeneration of injured or degenerated tissue, as 
a potential new therapeutic modality, draws lots of attention (Wislet-Gendebien et al., 2012). 
Stem cells have the potential to differentiate into many different cell types. Recent research 
has concerned an exciting opportunity to apply MSCs especially in the management of 
neurodegenerative diseases, because of their potential to differentiate into neurons (Lee et 
al., 2010).  
It has been shown that the injection of MSCs could be profitable in the treatment of 
neurodegenerative diseases such as Parkinson’s disease (Levy et al.), Spinal Stroke and 
cerebral ischemia (Sieber-Blum, 2010), Alzheimer's disease (Lee et al., 2010), Multiple 
Sclerosis (Grigoriadis et al., 2011), Huntington's Disease (Snyder et al., 2010). The 
advantages of using stem cells for regenerative medicine are not only the eases of harvesting 
from bone marrow or other donor sites but also the minimal risk of tissue rejection because 
of the application of autologous cells. 
Interestingly, recent data suggest that intravenously injected MSCs could migrate into the 
brain and pass blood-brain barrier (BBB), which is basically formed by brain microvascular 
endothelial cells (BMECs), and restrict the passage of immune cells and different molecules 
into the brain. The exact mechanism of this phenomenon, whether it is based on Integrin-
mediated adhesion or is matrix metalloproteinase dependent extracellular matrix 
degradation, is yet not clear (Krampera et al., 2007, Matsushita et al., 2011). 
One of the main clinical problems of stem cell transplantation is the difficulty of detection, 
localization, and examination of the stem cells in vivo at both cellular and molecular levels 
(Sandu et al.). State-of-the-art molecular imaging techniques provide new superior means of 
noninvasive, repeated, and quantitative tracking of stem cell implants or transplants (Sandu 
et al.). From initial deposition to the survival, migration, and differentiation of the 
transplant/implanted stem cells, current molecular imaging methods allow monitoring of 
the infused cells in the same live recipient bed over time (Sandu et al.). 
3. Positron Emission Tomography (PET) 
Over the past two decades, PET has been introduced and applied widly in the milieu of 
diagnosis including head and neck diseases. Along with a growing interest to use PET in 
tracing different types of molecules such as amino acids, receptor ligands, glucose and other 
metabolic substrates which follow specific metabolic pathways have been utilized to assess 
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different tissue functions, especially in neoplasms (Cornelius et al., 2011). The main 
substances for radio-labeling are fluorine-18 (F), gadolinium-68 (Ga) and Carbon-11 (C). The 
advantages that they confer upon other positron emitting isotopes such as O, N and C are 
their longer half-life time which results in superior tissue distribution and consequently a 
dynamic imaging of higher accuracy (de Langen et al., 2008, Keiding et al., 2010, Floeth et 
al., 2011, Henze et al., 2005). 
Among metabolic substrates, F-fluorodeoxyglucose is the most renowned molecular tracer 
in oncology. It has been shown that F-FDG uptake may increase in neoplasmic cells which 
are believed to be indicative of an increased glycolysis and a subsided respiratory rate of 
tumoral tissues (Di Chiro et al., 1987). It has been demonstrated that amino acid synthesis is 
up regulated in tumor cells in comparison to normal tissues. Until now, F-Tyrosine and C-
Methionine uptakes are studied at different grades of oncologic tumors such as 
meningimoma (Cremerius et al., 1997).  
C-colin, another marker which represents phospholipid synthesis, is hiked in malignant 
tumors. It has been shown that the metabolism and proliferation of C-colin are strongly 
correlated with breast and prostate cancers, indicating high uptake as a measurement of 
cellular proliferation (Cornelius et al., 2011). Other markers, with a better theoretical profile, 
have also been introduced in neuroscience but are mostly used only in a limited number of 
experiments, so that no knowledge is about their potential for imaging stem cell 
transplantation. 
4. Near-InfRared Fluorescence (NIRF) imaging 
NIRF confers similar capability for tracing of imaging agents as PET. NIRF dyes are 
chemically conjugated on targeting molecule such as antibodies, carbohydrates and 
peptides. After administration into tissues, the dye molecules are excited by the radiation of 
tissue penetrating NIR excitation light (750-900nm). 
Considering radioactive decay, a photon of lower energy which has a higher wavelength is 
emitted and the fluorescent dye relaxes back to its basic state, ready to repeat the same 
process. Each fluorescent dye absorb excitation light and afterward, just in a nanosecond, 
produce fluorescent light. Accordingly, each fluorescent dye molecule provides about 
100,000,000 photons per second for collection and image formation. As a consequence, low-
energy fluorescent photons are slightly absorbed and maximally scattered, reduced by the 
tissues between the targeted tissue and the tissue surface before being collected by detectors 
in a few milliseconds. In contrast with radionuclides, a fluorescent dye has no physical half-
life. Moreover, this methodology is not clinically approved yet and no devices is available 
for human imaging with NIRF contrast agents, and NIRF contrast imaging agents do not 
posses approval for human study as well. Interestingly, some investigators utilized NIRF 
imaging for human applications such as functional lymphatic imaging, sentinel lymph node 
mapping, activated probes, and promising advances in 3D imaging (Sevick-Muraca EM, 2012). 
5. Potential clinical applications of molecular imaging 
Many surgical techniques are mainly based on histological grading of the tumor. Molecular 
imaging enables surgeons to have the gross picture of these tumors. Pre-surgical molecular 
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imaging of neurological tumors enables us to establish better surgical procedure and 
strategy. Also, it would allow physicians to have a better pre-assessment of prognosis and 
risk benefit ratio. Moreover, PET might be helpful in the early discovery of molecular-level 
changes, which are undetectable in CT and MRI. Also, within a specific tumor, the most 
metabolically active and aggressive tumor areas could be mapped. 
Intriguingly, emerging data suggest that molecular imaging could be used as an outcome 
assessment tool for different treatment modalities. For instance, a recent study compared 
MRI response assessment with metabolic O-(2-(18)F-fluoroethyl)-L-tyrosine ((18)F-FET) PET 
response assessment during antiangiogenic treatment in patients with recurrent high-grade 
glioma (see table 1). Good results are already known for (18)FDG-PET, but results revealed 
that (18)F-FET PET, on the other hand, seems also to be predictive of treatment failure in 
that it contributes important information to response assessment based only on MRI and 









Table 1. (18)F-FDG Positron Emission Tomography with a Gold Standard of Biopsy or 
Radiography Follow-up (Schaller et al., 2008) 
6. Stem cell imaging at neurodegenerative pathways and pathologies 
Regenerative medicine is a developing era that seeks to restore or replace damaged tissue 
and organs via natural or bioengineered tools. Regenerative medicine via stem cells is 
considered as one of the most promising means to repair tissues. Stem cells could be isolated 
from both adult human and embryonic tissues. There is a great body of evidence 
demonstrating successful cases of expanded stem cell in vitro and then grafted in vivo for 
regenerative purposes at different tissues such as bone, cartilage, and myocardium.  
It seems that inflammation and degeneration are the two main aspects of CNS pathogenesis. 
It seems that there is an intrinsic connection between these two phenomena because in 
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several cases inflammation trigger degeneration. Also, endogenous neural stem cells, which 
have the capacity of renewing cells of CNS, may migrate to the affected area and robust the 
process of repair. This scenario drives scientists to seek a natural healing framework based 
on Trans stem cell therapy. In fact, it may improve the efficacy and decrease the toxicity of 
treatment modalities which are the main concepts of personalized medicine. 
7. Molecular imaging in Alzheimer’s disease 
Alzheimer’s disease (AD) is describes as a chronic and complex progressive 
neurodegenerative disorder, and is the most common cause of dementia among the elderly. 
A great body of evidences indicates that neuronal degeneration in AD progresses in a 
certain way while the pathology advances over several decades. Establishing an accurate 
dynamic map of this sequence is vital for the understanding and mapping the complex 
endophenotype of AD, providing a basis for successful treatments designed to resist or 
prevent disease progression. 
PET scanning has long been used to trace alterations in cerebral blood flow and metabolism 
in AD, and is useful for the differential diagnosis of dementia in individual patients. For 
instance, hypometabolism of the posterior cingulate cortex could be observed early in AD 
using fluoro-deoxyglucose (FDG) PET scanning, even while MRI results are normal (Ewers 
et al., 2011, Mosconi et al., 2004). As disease progresses, there is diminished cerebral 
metabolism and perfusion in posterior cingulate and association cortices, but the basal 
ganglia and thalamus, cerebellum, and primary sensorimotor cortices are largely spared 
until later stages of the disease. Some studies have tracked AD with PET, using new 
molecular probes sensitive to amyloid-beta (Aβ) or neurofibrillary tangle pathology, or both 
types of pathology (Braskie et al., 2010, Klunk et al., 2004, Mintun et al., 2006, Small et al., 
2006). 
8. Stem cell in Multiple Sclerosis (MS) 
Multiple sclerosis appears to result from defective innate and adaptive immune system 
actions in the CNS, likely begins with a kind of autoimmune response that leads to 
demyelination and neuronal degeneration. It seems that auto activity of immune system 
followed by neuroinflamation gradually causes death of oligodendrocytes. Increasing body 
of evidence represents that the brain’s inability to repair is one of the main factors that make 
this disease irreversible and causes permanent damages. This claim is in accordance with 
the fact that the progression of disease and state of remyelination is different in every 
patient. Consistently, Patrikios et al. (Patrikios et al.), recently performed 51 autopsies of MS 
patients with different clinical courses and disease durations and traced variable extents of 
remyelination. In 20% of patients – both relapsing and progressive patients – the extent of 
remyelination was extensive with 60–96% of the global lesion area remyelinated.  
Several attempts have been made since about four decades to replace demieylinated cells 
with myelin forming cells; however, as neural cells are highly differentiated and have 
limited ability for growth and expansion, these efforts have been mostly abortive in vivo. 
With the advent of stem cell regenerative medicine, scientists further discovered the 
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functional and special characteristics of adult stem cells and attempted to utilize them for 
the treatment of neurodegenerative multiple sclerosis. 
Adult stem cells have not only provided us with a readily available cell source for cell 
therapy but also with much safer and far less toxic tumor treatment measures. There are two 
basic routes for cell administration including in-site cell transplantation or blood injection 
(circulation). Tangible examples for the former include Parkinson’s disease, acute spinal 
cord injury and brain trauma. For multifocal diseases such as MS and epilepsy, the model of 
in-site injection is not effective; rather blood circulation or cerebrospinal fluid circulation 
should be used. There are several studies demonstrating successful results with the 
transplantation of hematopietic, mesenchymal and neural stem cells into the CNS injured 
areas in MS, SCI, epilepsy, and stroke cases (Pluchino et al., 2009). 
9. Mechanisms of Stem Cell Repairing 
A great amount of data demonstrates that HSCs have a great capacity to differentiate into 
different cell types including muscle, skin, neural tissue and lung (Pluchino et al., 2009). 
Several studies used HSCs injection as a treatment modality for hematological malignancies 
and shows that HSCs have the capability of entering the brain and as well as differentiating 
and producing new neural cells including neurons and microglia; these findings were in 
concordance by the detection of Y chromosome- positive Purkinje cells in the cerebellum of 
female rats who have undergone bone marrow transplantation from male donors (Koshizuka 
et al., 2004 2005). In addition, in an animal studies on rats suffering from a demyelinated lesion 
of the spinal cord, intravenous or intraparenchimal HSCs therapy lead to different degrees of 
remyelination  which  was proportional to the number of injected stem cells (Akiyama et al., 
2002a 2002, Inoue et al, 2003, Akiyama et al., 2002b 2002, Inoue et al, 2003). 
Several studies have challenged the idea of cell replacement in stem cell regeneration 
theories. Despite the fact that MSCs can exert various therapeutic effects, some data suggest 
that they protect immune system from demyelination via alternative mechanism to cell 
replacement.  
The suggested therapeutic effect is based on the intrinsic capacities of such cells to secret a 
large number of cytokines and chemokines. It has been shown that the pattern of secretion 
changes as early as transplanted stem cell encounter new (micro) environment in vivo. Some 
studies have shown that mesenchymal stem cells mainly act by suppressing inflammation, 
via cell-to-cell contact as well as through the activation of anti-inflammatory pathways; and 
consequently the proliferation, migration and differentiation of endogenous progenitor cells 
are enhanced. 
Utilizing fluorescent dyes and imaging modalities in humans is not possible due to limited 
depth of tissue penetration.  On the other hand, magnetic resonance imaging (MRI) and 
positron emission tomography (PET) have shown promising value and also great feasibility 
for treatment via stem cell. As well as above PET scan imaging, stem cells could be tagged 
with ferromagnetic material or with gadolinium rhodamine dextran and then detect via  
MRI (Brekke et al., 2007) (Carney and Shah, 2011). These imaging modalities along with 
alteration of genes via genetic engineering  and consequent labeling methods, enabled 
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scientists to monitor  different phase of repair and stem cell therapy. This allows not only 
the imaging in real time of stem cell migration, but also its integration, and therapeutic 
effects at the single cell level. Also, the above-mentioned capacities for tracing and 
monitoring of grafted stem cell behavior, enable us to assess both quantitatively and 
qualitatively the interaction between stem cell and its environment.  
10. View to the future 
Molecular imaging will gain more and more importance in neurosciences. PET is currently 
the gold standard and that will not change very soon. However, the different methods have 
different advantages and disadvantages, but it is not only for the researcher but also for the 
physician important to know this differences. In the near future, imaging on the molecular 
but also on the cellular level will not be an exception, as it is still now, but rather the rule. 
Such improvements open widely the door to a personalized medicine, a fact that has special 
importance in neurosciences. 
11. Take-home-message 
Molecular imaging has gained step-by-step importance in neuroscience. To know this 
method in detail is demanding but important in the area of personalized medicine. 
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